Alkermes (ALKS) Total Non-Current Liabilities (2011 - 2026)

Alkermes' (ALKS) quarterly Total Non-Current Liabilities came in at $2.4 billion in Q1 2026, up 368.59% year-on-year from $511.5 million in Q1 2025, and up 259.0% on a QoQ basis from $667.7 million in Q4 2025.

Alkermes (ALKS) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends

Alkermes (ALKS) has 16 years of Total Non-Current Liabilities data on file, last reported at $2.4 billion in Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities rose 368.59% year-over-year to $2.4 billion in Q1 2026; TTM through Mar 2026 was $2.4 billion, a 368.59% increase from a year earlier, with the FY2025 full-year figure at $667.7 million, up 24.9% from the prior year.
  • Total Non-Current Liabilities for Q1 2026 stood at $2.4 billion, up from $667.7 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for ALKS reached as high as $2.4 billion in Q1 2026 and fell as low as $511.5 million in Q1 2025.
  • Historically, Total Non-Current Liabilities has averaged $860.6 million across 5 years, with a median of $856.2 million in 2022.
  • Across the five-year window, Total Non-Current Liabilities sank 39.5% in 2024 and soared 368.59% in 2026, its largest moves.
  • Year by year, Total Non-Current Liabilities stood at $877.8 million in 2022, then rose by 0.66% to $883.7 million in 2023, then sank by 39.5% to $534.6 million in 2024, then grew by 24.9% to $667.7 million in 2025, then surged by 259.0% to $2.4 billion in 2026.
  • Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $2.4 billion in Q1 2026, $667.7 million in Q4 2025, and $539.3 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 14.92 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 18.28 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 11.64 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 33.47 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 599.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 20.09 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 1.24 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 6.26 Bn
10 Alkermes 9.72 Bn 9.21 Bn 331.33 Mn 2.40 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 2.40 Bn
Dec 31, 2025 667.70 Mn
Sep 30, 2025 539.33 Mn
Jun 30, 2025 572.18 Mn
Mar 31, 2025 511.54 Mn
Dec 31, 2024 534.57 Mn
Sep 30, 2024 810.56 Mn
Jun 30, 2024 874.54 Mn
Mar 31, 2024 820.17 Mn
Dec 31, 2023 883.66 Mn
Sep 30, 2023 870.03 Mn
Jun 30, 2023 858.53 Mn
Mar 31, 2023 868.66 Mn
Dec 31, 2022 877.84 Mn
Sep 30, 2022 856.19 Mn
Jun 30, 2022 829.89 Mn
Mar 31, 2022 858.55 Mn
Dec 31, 2021 868.25 Mn
Sep 30, 2021 867.15 Mn
Jun 30, 2021 803.34 Mn